AUR109

Phase 2Small molecule

AAurigene Discovery Technologies Limited

AUR109 is one of 3 small molecule programs targeting Renal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Renal CancerRecruiting

Renal CancerPhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Renal Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Phase 2

1 2

Opdivo

Bristol-Myers Squibb

Phase 2

1 3

AUR109

AAurigene Discovery Technologies Limited

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Renal Cancer

NCT06760702

Clinical

Trials by Indication[1]

Renal Cancer1 trial

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients with Colorectal, Ovarian, and Renal Cancers

Recruiting·AAurigene Discovery Technologies Limited·Phase 2·NCT06760702·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AUR109. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AUR109 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AUR109. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aurigene Discovery Technologies Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAurigene Discovery Technologies Limited

AUR109

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Renal Cancer1 trial

References

Drug Info

Quick Facts

Related News